Literature DB >> 2349880

Rapidly progressive type III Gaucher disease: deterioration following partial splenectomy.

M Kyllerman1, N Conradi, J E Månsson, A K Percy, L Svennerholm.   

Abstract

Total splenectomy has been found to accelerate disease progression in Type III Gaucher disease, therefore partial splenic resection was performed in a 28 month old girl with rapidly progressive (non-Norrbottnian) Type III disease to alleviate the effects of hypersplenism. Surgery failed to arrest the disease process and splenomegaly recurred within three months. The erythrocyte glucosylceramide level increased post-operatively. Post-mortem studies revealed dense accumulation of Gaucher cells in spleen, liver, lungs, bone marrow and within the central nervous system. The glucosylceramide content of brain and liver was elevated to the range previously noted in splenectomised Norrbottnian patients. Thus, in rapidly progressive Type III Gaucher disease, neither total nor partial splenectomy alone provides a favourable outcome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2349880     DOI: 10.1111/j.1651-2227.1990.tb11492.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  9 in total

Review 1.  Management of neuronopathic Gaucher disease: a European consensus.

Authors:  A Vellodi; B Bembi; T B de Villemeur; T Collin-Histed; A Erikson; E Mengel; A Rolfs; A Tylki-Szymanska
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

2.  Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients.

Authors:  R A O'Reilly
Journal:  West J Med       Date:  1998-08

3.  Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings.

Authors:  N Conradi; M Kyllerman; J E Månsson; A K Percy; L Svennerholm
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Effective cell and gene therapy in a murine model of Gaucher disease.

Authors:  Ida Berglin Enquist; Eva Nilsson; Andreas Ooka; Jan-Eric Månsson; Karin Olsson; Mats Ehinger; Roscoe O Brady; Johan Richter; Stefan Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-05       Impact factor: 11.205

5.  Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice.

Authors:  Maria Dahl; Alexander Doyle; Karin Olsson; Jan-Eric Månsson; André R A Marques; Mina Mirzaian; Johannes M Aerts; Mats Ehinger; Michael Rothe; Ute Modlich; Axel Schambach; Stefan Karlsson
Journal:  Mol Ther       Date:  2015-02-06       Impact factor: 11.454

6.  Murine models of acute neuronopathic Gaucher disease.

Authors:  Ida Berglin Enquist; Christophe Lo Bianco; Andreas Ooka; Eva Nilsson; Jan-Eric Månsson; Mats Ehinger; Johan Richter; Roscoe O Brady; Deniz Kirik; Stefan Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

7.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

Review 8.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

Review 9.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.